University of Tennessee West Cancer Center | Strategic Alliance Partners

Jason Porter, MD, discusses potential sequencing strategies with antibody-drug conjugates and TKIs in HER2-positive lung cancer.

David C. Portnoy, MD, FACP, discusses ongoing studies examining immunotherapy and what is needed to move the needle forward in SCLC.

Axel Grothey, MD, discusses the potential utility of trifluridine/tipiracil in combination with bevacizumab in metastatic colorectal cancer.

Axel Grothey, MD, discusses dosing strategies with regorafenib in colorectal cancer.

Axel Grothey, MD, discusses the excitement surrounding HER2-directed therapies in gastrointestinal malignancies, the approval of trastuzumab deruxtecan in HER2-positive metastatic gastric/gastroesophageal junction cancer, and the investigational agents patritumab deruxtecan and zanidatamab that are poised to further advance the paradigm.

Axel Grothey, MD, discusses the rationale to evaluate patritumab deruxtecan in HER3-positive colorectal cancer.

Fam-trastuzumab deruxtecan-nxki is under study alone and in combination for the treatment of patients with HER2-overexpressing locally advanced, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma in the ongoing phase 1b/2 DESTINY-Gastric03 trial.

Axel Grothey, MD, discusses potential combination strategies with fam-trastuzumab deruxtecan-nxki in gastrointestinal malignancies.

Axel Grothey, MD, highlights recent advancements in CRC treatment, including innovative combinations and emerging agents that are generating excitement in the field.

Axel Grothey, MD, discusses the results of the phase 2 ANCHOR-CRC trial in patients with BRAF-mutant metastatic colorectal cancer.

Axel Grothey, MD, discusses the DESTINY-CRC01 trial in patients with HER2-positive colorectal cancer.

Axel Grothey, MD, discusses the role of precision medicine in colorectal cancer.

Axel Grothey, MD, discusses investigational combination therapies in microsatellite instability–high colorectal cancer.

Axel Grothey, MD, discusses combination therapies with regorafenib and trifluridine/tipiracil in colorectal cancer.

Noam VanderWalde, MD, MS, discusses the importance of implementing multidisciplinary care for patients with rectal cancer.

Axel Grothey, MD, discusses factors to consider when selecting between regorafenib and trifluridine/tipiracil in metastatic colorectal cancer.

Axel Grothey, MD, discusses left- versus right-sided tumors in colorectal cancer.

Axel Grothey, MD, explains the impact of tumor sidedness on treatment decisions and highlights novel later-line approaches that are under examination in colorectal cancer.

Noam VanderWalde, MD, MS, discusses radiation therapy in early-stage versus later-stage rectal cancer.

Axel Grothey, MD, discusses biomarkers that can help to guide the treatment of metastatic colorectal cancer.

Bradley G. Somer, MD, discusses the impact of the phase 3 IMbrave150 trial on the treatment of patients with unresectable hepatocellular carcinoma.

Bradley G. Somer, MD, discusses shifts in the hepatocellular carcinoma treatment paradigm, pivotal trials that have generated excitement, and sequencing approaches.

Noam VanderWalde, MD, MS, highlights the importance of multidisciplinary care for rectal cancer and few key studies that have impacted treatment.

Noam VanderWalde, MD, MS, discusses ​where future research ​efforts should focus in rectal cancer. 

Bradley G. Somer, MD, discusses the clinical implications of the FDA approval of atezolizumab in combination with bevacizumab in unresectable or metastatic hepatocellular carcinoma.

Lee Schwartzberg, MD, FACP, advocates for the increased use of biosimilars in oncology and discusses the benefits of these agents for patients and providers.

Kurt W. Tauer, MD, FACP, discusses the expansion of subtyping in breast cancer.

Gregory Vidal, MD, PhD, assistant professor, Department of Hematology/Oncology, The University of Tennessee Health Science Center, and medical oncologist, West Cancer Center, discusses the potential use of CDK4/6 inhibitors in HER2-positive breast cancer.

Gregory Vidal, MD, PhD, discusses how the field will determine which trastuzumab (Herceptin) biosimilar to prescribe in clinical practice.

Experts from West Cancer Center highlighted the exciting research being conducted at their institution.